The Flow Cytometry Core Core is a fee-for-service facility providing flow cytometry instrumentation and expertise to members of the University of Michigan Comprehensive Cancer Center (UM-CCC). The Flow Core has been in continuous operation since 1964 with the main facility residing in dedicated laboratory space provided by the Comprehensive Cancer Center since 1997, For calendar year 2010 there were 95 UM-CCC-affiliated members using the facility, accounting for 51% of the core user base (187 total users) while accounting for 82% of total flow core usage. The Flow Core also provides access to all UM investigators in a broad range of basic and medical sciences. Investigators deliver pre-processed samples to the Core for flow cytometric analysis and/or cell sorting. The core operates on a fee-for-service basis, with a recharge rate of $120/hour. Comprehensive Cancer Center Investigators are able to bill 50% of their usage directly to the CCC core support grant. Recharge rates are further discounted for those investigators willing to provide self-operation on unstaffed Instrumentation. Instruments are operated by trained flow cytometry operators (7.6 FTEs). Access to the facility Is reserved in advance (24-hour minimum) on a first-come basis. Core instrumentation includes one Coulter MoFlo XDP multilaser high-speed ceil sorter, three BD Biosciences FACSAria multilaser high-speed cell sorters, two BD Biosciences FACSDIVa multilaser high-speed cell sorters, a Coulter Cyan multilaser analzer, two BDBiosciences FACSCanto II analyzers, two BD Biosciences FACSCalibur multilaser analyzers, and a Coulter Z2 Particle Counter.

Public Health Relevance

The study of human clinical disease necessitates the ability to Identify and isolate discrete populations of human cells. The University of Michigan Flow Cytometry Core Facility provides a broad range of Instrumentation and expertise to researchers in the University of Michigan Comprehensive Cancer Center.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Michigan Ann Arbor
Ann Arbor
United States
Zip Code
Owen, John Henry; Graham, Martin P; Chinn, Steven B et al. (2016) Novel method of cell line establishment utilizing fluorescence-activated cell sorting resulting in 6 new head and neck squamous cell carcinoma lines. Head Neck 38 Suppl 1:E459-67
Lee, Alice W; Ness, Roberta B; Roman, Lynda D et al. (2016) Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstet Gynecol 127:828-36
Mathewson, Nathan D; Jenq, Robert; Mathew, Anna V et al. (2016) Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol 17:505-13
Boonstra, Philip S; Mukherjee, Bhramar; Gruber, Stephen B et al. (2016) Tests for Gene-Environment Interactions and Joint Effects With Exposure Misclassification. Am J Epidemiol 183:237-47
Peng, Dongjun; Tanikawa, Takashi; Li, Wei et al. (2016) Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling. Cancer Res 76:3156-65
Kadakia, Kunal C; Snyder, Claire F; Kidwell, Kelley M et al. (2016) Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer. Oncologist 21:539-46
Boonstra, Philip S; Taylor, Jeremy M G; Smolska-Ciszewska, Beata et al. (2016) Alpha/beta (α/β) ratio for prostate cancer derived from external beam radiotherapy and brachytherapy boost. Br J Radiol 89:20150957
Amin, Nisar A; Malek, Sami N (2016) Gene mutations in chronic lymphocytic leukemia. Semin Oncol 43:215-21
Hardiman, Karin M; Ulintz, Peter J; Kuick, Rork D et al. (2016) Intra-tumor genetic heterogeneity in rectal cancer. Lab Invest 96:4-15
Zhao, Ende; Maj, Tomasz; Kryczek, Ilona et al. (2016) Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol 17:95-103

Showing the most recent 10 out of 1165 publications